11. Sources and clinical references

Disease-specific MASTER-level citations. The CMS coverage categories (Pub. 100-02 Ch. 7), the Conditions of Participation (42 CFR Part 484), and OASIS-E2 are carried in the parent assessment modules and Foundations and are not repeated here. The patient's ordered parameters always control over any general guideline target.

• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (Joglar JA, et al. Circulation. 2024;149(1):e1–e156; co-published in J Am Coll Cardiol. 2024;83:109–279). Thromboembolic risk assessment and anticoagulation in atrial fibrillation, including direct oral anticoagulant use.
• Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report (Stevens SM, et al. CHEST. 2021;160(6):e545–e608; executive summary 2021;160(6):2247–2259), with the consolidated current statements in “Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012–2021” (Stevens SM, et al. CHEST. 2024;166(2):388–404).
• Community Health Accreditation Partner (CHAP) Standards of Excellence for Home Health. [Insert the exact standard title, version, section, and effective date per the edition held by the agency.]

Usage note: Every narrative and smart phrase in this module is a structured example to be edited to reflect what was actually assessed and the patient's specific orders. Documentation must reflect the real visit; do not copy unchanged.